Gilead’s HIV prevention treatment found 100% effective in late-stage trial

Gilead Sciences Inc.’s stock jumped early Thursday after the company said its experimental injection for HIV prevention was found 100% effective in a late-stage trial.

Previous post Jobless claims stay near a 10-month high. The end of the school year might be the reason.
Next post This indicator suggests unloved small-cap stocks may be poised for a turnaround